Analisi dei costi diretti sanitari associati alla Fibrillazione Atriale non Valvolare in real life
Simona Cammarota, Antonella Guida, Marco Barletta, Anna Citarella, Paolo Capogrosso, Sara Carotenuto,
Maria Concetta Conte, Claudia De Marino, Pasquale Izzo, Raffaele Piscitelli, Francesca Romagnuolo, Gennaro Ratti,
Ugo Trama, Simona Creazzola
Introduction: The growing epidemic of atrial fibrillation (AF), with its associated morbidity and mortality, is rendering this disease a public health crisis. Such information is valuable for decision makers when targeting how to improve the efficiency of care delivery for those with a particular health condition. The aim of the study was to determine the direct healthcare costs associated with non-valvular atrial fibrillation (NVAF).
Materials and Methods: A population-based cohort study was conducted using administrative data from a local health authority in the Campania Region ( 1,000,000 inhabitants). NVAF was defined as one or more claims for atrial fibrillation (ICD-9-CM code 427.31) between January 1, 2005 and June 30, 2014, where none of the claims was associated with cardioversion or cardiac ablation and there was no evidence of valve-related diagnoses or procedures. All patients were followed from June 30, 2014 until death or end of study follow-up (December 31, 2014). The direct costs were reported as average annualized cost (per patient per month multiplied by 12). Costs were divided into hospitalizations, outpatient services and pharmacy claims. Generalized linear mixed models under gamma distribution were used to identify predictors of cumulative healthcare costs. Rate Ratios (RRs) and 95% confidence intervals (CIs) were adjusted for age, gender, CHA2DS2-VASc and HAS-BLED clinical risk score.
Results: Totally, 10,099 patients fulfilled our study criterions. The total annualized direct cost of NVAF patient was € 1,627.9 ±1,076.6. The main cost component was the hospitalization (68.0%), followed by drug use (24.6%) and out-patient services (7.4%). The predictors of the total cost were male (RR: 1.43, 95%CI: 1.34-1.52 versus female), CHA2DS2-VASc score (RR: 4.55, 95%CI:3.59-5.78 for score 7 versus score 0).
Conclusions: NVAF places an enormous burden on health care system. Hospitalization as major cost driver highlights the potential cost-effectiveness of disease management targeted at reducing risks of serious cerebrovascular events among NVAF patients.
Key words: Non Valvular Atrial Fibrillation (NVAF), healthcare cost, real world data, CHA2DS2-VASc, administrative data